New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT06100874
First seen Feb 21, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study tests a combination of two drugs, sacituzumab govitecan and trastuzumab, in 28 people with HER2+ breast cancer that has spread and has been previously treated. The goal is to see if this combination can shrink tumors or slow cancer growth. Participants receive both drugs intravenously, and the study tracks how many respond and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DFCI @ South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana Farber Cancer Institite
Boston, Massachusetts, 02215, United States
-
Miami Cancer Institute at Baptist Health
Miami, Florida, 33176, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.